研究论文开放获取

PB2171 Marstacimab in Severe Haemophilia B without inhibitors: First UK Real-World Experience – A Case Series

Jireh Ann L. Batac, Amy Knott

Hull University Teaching Hospitals NHS Trust

来源Research and Practice in Thrombosis and Haemostasis

年份2026

DOI10.1016/j.rpth.2026.104911

原文https://doi.org/10.1016/j.rpth.2026.104911

阅读操作

确认中

在文库中上传 PDF 后可生成中文音频讲解。

摘要与影响

摘要 · 完整

Marstacimab is a once-weekly subcutaneous anti-TFPI monoclonal antibody that reduces annual bleeding rates with a favourable safety profile. NHS England approved its use from 2025 for people ≥12 years with severe haemophilia B without inhibitors, the first rebalancing therapy for this group.

逐年被引趋势

暂无年度引用数据

关键指标

被引次数 · OpenAlex

领域内被引倍数
同类平均 = 1

引用位次
同领域 · 同年份 · 同类型

参考文献

Google Scholar 与 OpenAlex 的被引统计范围不同，数值存在差异属正常。

AI 辅助阅读

依据：摘要

论文问答

当前基于摘要回答

可就本文提问；依据不足时会说明。

学术脉络

学科主题

生物医学

Hemophilia Treatment and Research

Platelet Disorders and Treatments · Coagulation, Bradykinin, Polyphosphates, and Angioedema

参考文献 0

暂无参考文献明细

引用本文 -

暂无引用本文的记录